Immunooncology

I'm your host, Alex Gray.

Everybody, to part two of our Future of Immuno-Oncology podcast discussion.

In part one, we looked back at, you know, where we've been with the immuno-colo- oncology market, focused a lot on Keytruda and Opdivo and how, you know, that battle over time played out and how it ultimately came down to the strategic decisions made by Keytruda that led to some of the differences that we ultimately have seen across oncology, versus either of those assets being intrinsically differentiated from each other.

In part two today, what we wanna do is look at the future and, you know, think about what comes next in immuno-oncology, what could the future look like, which companies might be better positioned to be the winners, what strategies are they pursuing, you know, what mechanisms are, you know, showing promise.